Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indi-Blade
2024-512211-41-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in transitional cell carcinoma of the bladder (TCC) and bladder cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Bladder-intact event-free survival (BI-EFS). Planned start Oct 2024; status: authorised.
02
Drugs
nivolumabipilimumab
03
Conditions
transitional cell carcinoma of the bladder (TCC)bladder cancer
Beyond the preview
Go deeper on 2024-512211-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512211-41-00.